News
Novo Nordisk reported positive data from a late-stage trial of its once-weekly Sogroya treatment for children with growth disorders.
The Royal Danish Embassy and Novo Nordisk co-hosted the first Danish-Thai Obesity Policy Forum to address Thailand’s rising ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback